Challenges for the National Institute for Clinical Excellence
- PMID: 15271837
- PMCID: PMC487743
- DOI: 10.1136/bmj.329.7459.227
Challenges for the National Institute for Clinical Excellence
Abstract
So far NICE has focused on evaluating new technologies rather than existing ones. But this approach is creating inflationary pressure that the NHS cannot afford
Comment in
-
NICE and its value judgments: favourable appraisal amounts to compulsory purchase order.BMJ. 2004 Sep 25;329(7468):740-1; author reply 741. doi: 10.1136/bmj.329.7468.740-b. BMJ. 2004. PMID: 15388620 Free PMC article. No abstract available.
Comment on
-
National Institute for Clinical Excellence and its value judgments.BMJ. 2004 Jul 24;329(7459):224-7. doi: 10.1136/bmj.329.7459.224. BMJ. 2004. PMID: 15271836 Free PMC article.
Similar articles
-
National Institute for Clinical Excellence and its value judgments.BMJ. 2004 Jul 24;329(7459):224-7. doi: 10.1136/bmj.329.7459.224. BMJ. 2004. PMID: 15271836 Free PMC article.
-
NICE and its value judgments: option of safe "understudy" treatments should be available.BMJ. 2004 Sep 25;329(7468):740; author reply 741. doi: 10.1136/bmj.329.7468.740. BMJ. 2004. PMID: 15388622 Free PMC article. No abstract available.
-
NICE and its value judgments: utilitarian values are inadequate.BMJ. 2004 Sep 25;329(7468):740; author reply 741. doi: 10.1136/bmj.329.7468.740-a. BMJ. 2004. PMID: 15388621 Free PMC article. No abstract available.
-
The National Institute for Clinical Excellence (NICE).Ann Rheum Dis. 2002 Nov;61 Suppl 2(Suppl 2):ii92-5. doi: 10.1136/ard.61.suppl_2.ii92. Ann Rheum Dis. 2002. PMID: 12379636 Free PMC article. Review. No abstract available.
-
The National Institute for Clinical Excellence and the RCM.RCM Midwives J. 2002 Aug;5(8):260-1. RCM Midwives J. 2002. PMID: 12242758 Review.
Cited by
-
The increasingly complex fourth hurdle for pharmaceuticals.Pharmacoeconomics. 2007;25(9):727-34. doi: 10.2165/00019053-200725090-00002. Pharmacoeconomics. 2007. PMID: 17803332
-
The generalisability of pharmacoeconomic studies: issues and challenges ahead.Pharmacoeconomics. 2006;24(10):937-45. doi: 10.2165/00019053-200624100-00001. Pharmacoeconomics. 2006. PMID: 17002476 Review.
-
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.Pharmacoeconomics. 2008;26(2):91-8. doi: 10.2165/00019053-200826020-00001. Pharmacoeconomics. 2008. PMID: 18198930 Review.
-
NICE guidelines on anti-tumor necrosis factor therapy for RA.Nat Clin Pract Rheumatol. 2009 Jan;5(1):16-7. doi: 10.1038/ncprheum0964. Epub 2008 Dec 2. Nat Clin Pract Rheumatol. 2009. PMID: 19048006 No abstract available.
-
Information created to evade reality (ICER): things we should not look to for answers.Pharmacoeconomics. 2006;24(11):1121-31. doi: 10.2165/00019053-200624110-00008. Pharmacoeconomics. 2006. PMID: 17067196 Review.
References
-
- Association of the British Pharmaceutical Industry. The expert patient. London: ABPI, 1999. www.abpi.org.uk/publications/publication_details/expert_patient/power_po... (accessed 14 October 2003).
-
- Williams A. Intergenerational equity: an exploration of the fair innings. Health Economics 1997;6: 117-32. - PubMed
-
- Freemantle N, Bloor K, Eastaugh J. A fair innings for NICE? Pharmacoeconomics 2002;20: 389-91. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources